Highest-materiality recent filing
Beyond Air approves 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse stock split at 1-for-20 ratio, effective 12:01 a.m. ET on July 13, 2026.
Beyond Air reports 107% revenue growth in FY2026; guides $8M for CY2026, $16-18M for CY2027
Revenue FY2026 $7.7M (+107% YoY); Q4 $1.9M (+66%). Net loss per share ($4.01) vs ($13.77) prior year.
Beyond Air stockholders approve 1-for-20 reverse stock split to regain Nasdaq compliance
Stockholders approved reverse split at special meeting June 18, 2026; 5,177,506 for, 1,222,793 against.
Nasdaq Hearings Panel granted continued listing subject to regaining Bid Price Rule compliance by July 31, 2026.
Beyond Air receives Nasdaq delisting notice for bid price non-compliance; hearing requested
Nasdaq Staff notified Beyond Air that its common stock failed to maintain minimum $1.00 bid price per Listing Rule 5550(a)(2).
Nasdaq notified Beyond Air on Apr 7, 2026 that it fails Bid Price Rule; stock closed below $1 for 30 consecutive business days through Apr 6.
Beyond Air CEO Steve Lisi resigns; Robert Goodman appointed CEO effective March 27, 2026
Steve Lisi resigned as CEO and director, effective March 27, 2026; no disagreement with the Company.
Beyond Air Q3 revenue up 105% to $2.2M, net loss narrows; FY2026 guidance reaffirmed at $8-10M
Revenue $2.2M, up 105% YoY; gross profit $0.3M vs ($0.2M) gross loss prior year.
Beyond Air raises $5M in private placement of stock and warrants at $1.272/unit
Gross proceeds of $5.0M from sale of 3,930,818 shares (or pre-funded warrants) and five-year warrants at $1.147 strike.
XTL to acquire 85% of Beyond Air's NeuroNOS for equity, $1M cash, up to $32.5M milestones
XTL acquires 85% of NeuroNOS for 19.9% of XTL's share capital, $1M cash, and up to $32.5M in milestone payments.
Beyond Air Q2 revenue up 128% to $1.8M; net loss narrows; secures $32M financing
Revenue $1.8M (+128% YoY); net loss ($7.9M) ($1.25/share) vs. ($13.4M) ($5.67/share).
Beyond Air secures up to $32M in financing from Streeterville Capital
Issued $12M promissory note with 15% annual interest; net proceeds ~$12M; $6M placed in restricted account.
Beyond Air receives ~$3.25M from warrant exercise; issues new warrants for 719,561 shares
Gross proceeds ~$3.25M from immediate exercise of 1,439,126 existing warrants at reduced price of $2.21/share.
NeuroNOS (Beyond Air unit) receives FDA Orphan Drug Designation for BA-101 in glioblastoma
FDA grants Orphan Drug Designation for BA-101, an investigational nNOS inhibitor, for treatment of glioblastoma.
Beyond Air Q1 revenue rises 157% to $1.8M; net loss narrows to $7.7M
Revenue $1.8M vs $0.7M YoY (+157%); gross profit $0.2M vs loss of $0.3M.
Beyond Air announces 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse stock split ratio 1-for-20, effective July 14, 2025.
Beyond Air shareholders approve reverse stock split at up to 1-for-50 ratio
Shareholders approved reverse stock split ratio between 1-for-10 and 1-for-50, as determined by the Board.
Beyond Air Q4/FY2025 revenue $3.7M (+220% YoY); guides FY2026 $12-16M; filed PMA for LungFit PH II
Revenue $3.7M for FY2025, up 220% YoY; net loss $46.6M ($0.69 per share).
Beyond Air expands LungFit PH distribution to 4 new countries; director resigns
Distribution agreements now cover France, Romania, Turkey and Morocco; total reaches 18 countries.
Beyond Air Q3 FY2025 revenue $1.1M (+34% QoQ); cash burn $7.6M; CE Mark for LungFit PH in Europe
Revenue $1.1M for Dec 31, 2024 quarter, up 34% from $0.8M in prior quarter and up from $0.4M YoY.
Beyond Air granted 180-day Nasdaq extension to Aug 4, 2025 to meet $1.00 bid price
Second compliance period runs until August 4, 2025; must close at $1.00+ for 10 consecutive business days.
Israeli Ministry of Health approved Phase 1b trial of LV UNO in combination with anti-PD-1 therapy for solid tumors.
CE mark approval allows Beyond Air to market LungFit PH in the European Union and other recognizing countries.
Beyond Air Q2 FY2025 revenue $0.8M (+17% QoQ); extends cash runway through June 2026
Revenue $0.8M vs $0.2M YoY; cost of revenue $1.9M (depreciation & upgrade costs).
Beyond Air secures $11.5M secured loan from CEO and director; issues warrants
$11.5M loan at 15% interest (3% cash, 12% PIK through June 2026); matures Oct 2034.
Beyond Air enters $11.5M secured loan with CEO and director; 15% PIK interest, 8% royalty
Term sheet for $11.5M secured loan from CEO Steven Lisi and director Robert Carey; 10-year term, 15% PIK interest through July 2026.
Sold 40,392,155 shares/pre-funded warrants at $0.51/$0.5099 per unit with warrants exercisable at $0.38 for 5 years.
Revenue $0.7M, up 45% QoQ from $0.5M; net loss $12.2M ($0.27/share) vs $14.1M ($0.45) year ago.
FY2024 revenue $1.2M (vs. $0); net loss $60.2M ($1.82 loss per share).
Beyond Air appoints David Webster as Chief Commercial Officer effective July 8, 2024
David Webster appointed CCO, effective July 8, 2024, with over 20 years life sciences experience.
Beyond Air raises $16M via registered direct offering of 9.6M shares & warrants at $1.66
Gross proceeds of $16M from sale of 9,638,556 shares and warrants at combined price $1.66 per unit.
Beyond Air Q3 FY2024 net loss $16.2M; revenues $0.4M; FY2025 guidance reiterated $12-16M
Net loss $16.2M ($0.50 per share) vs $12.7M ($0.43) in Q3 FY2023; revenues $0.4M from zero prior year.
Beyond Air Q2 net loss widens to $16.2M; guides FY2025 revenue $12-$16M
Revenue $0.24M vs $0 prior year; net loss $16.2M ($0.51 loss per share) vs $12.0M ($0.40) prior year.
Beyond Air Enters Distribution Agreement with Getz Healthcare for LungFit PH in Asia-Pacific
Getz Healthcare to make $1,000,000 milestone payment upon CE mark certification of LungFit PH in Europe.
Beyond Air Q1 FY2024 revenue $0.1M (first commercial); net loss $14.1M; secured $40M debt facility
Revenue of $0.1M from commercial LungFit PH sales; cost of revenue $0.3M.
Beyond Air reports $59.4M net loss for FY2023; secures $40M debt facility
GAAP net loss of $59.4M ($55.8M attributable, $1.86 per share) vs $43.2M ($1.68) prior year.
Beyond Air secures up to $40M debt financing; $17.5M funded at close
$17.5M advanced on June 15, 2023; up to $22.5M more available upon meeting milestones.
Beyond Air appoints Jeff Myers, M.D., Ph.D. as Chief Medical Officer effective March 27, 2023
Dr. Myers brings ~15 years of biopharmaceutical executive experience and was previously a cardiothoracic surgeon at Massachusetts General Hospital.
On June 16, 2025, the Board of Directors (the “Board”) of the Company appointed Robert Goodman as a member of the Board.
On March 14, 2025, Ron Bentsur resigned from the board of directors of Beyond Air, Inc.
tendered his resignation from the board of directors of the Company and as the Chief Business Officer of the Company.
tendered his resignation from the board of directors of the Company and as the Chief Business Officer of the Company.
On August 6, 2024, Amir Avniel was appointed Chief Executive Officer of NeuroNOS Israel Limited overseeing the Company’s autism spectrum disorder program and tendered his resignation from the board of directors of the Company and as the Chief Business Officer of the Company.
On June 28, 2022, the Board of Directors (the “Board”) of Beyond Air, Inc. (the “Company”) appointed Michael Gaul, age 68, as the Company’s Chief Operating Officer, effective July 1, 2022
On August 20, 2021, the Board of Directors (the “Board”) of Beyond Air, Inc. (the “Company”) appointed Douglas Larson, age 51, as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective September 1, 2021 (the “Start Date”).
Max materiality 0.80 · Median 0.65 · Most common event other_material